Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Senior who wrote (55904)	8/19/2015 3:20:31 PM
From: E_K_S	Read Replies (1) of 78717

Opko Health, Inc. (NYSE: OPK) Bio-Reference Laboratories Inc. (NASDAQ: BRLI) Not really a value Buy but more of a GARP play (more emphasis on growth). These two companies to vote on merger tomorrow. The conversion ratio is 2.75:1 BRLI:OPK. BRLI generates the revenues and OPK has a prostate cancer diagnosis test recently approved by FDA. Combined their diagnosis tests will be used in labs and hospital around the world. They are also developing and selling a Web based portal service for Lab results that s/d help them expand their footprint to more HMO's and end users. BRLI selling at a 19 PE and OPK should be profitable once it's 4Kscore prostate test is available to the labs/hospital network. Trying to build out my medial/pharma exposure and this was one area (test diagnosis sector) that you can buy that has earnings and growth for a reasonable price. EKS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next